Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

0.5597 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.5597
Bid (Size) 0.5500 (14)
Ask (Size) 0.5800 (7)
Prev. Close 0.5597
Today's Range 0.5597 - 0.5597
52wk Range 0.5597 - 19.90
Shares Outstanding 4,063,081
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Biora Therapeutics (BIOR) Stock Is Down 45%
Biora Therapeutics shares are trading lower by 45% during Tuesday's session. The company announced that it will be delisted from Nasdaq. 
Via Benzinga

Performance

YTD
-95.79%
-95.79%
1 Month
-65.66%
-65.66%
3 Month
-90.14%
-90.14%
6 Month
-91.89%
-91.89%
1 Year
-95.63%
-95.63%

More News

Read More
Dow Falls 150 Points; Oracle Posts Downbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics's Earnings Outlook
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Achieves ISO 13485 Certification
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Positive Nasdaq Listing Decision
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Funding Agreement with Existing Investors
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.